Table 1 Population parameter estimates obtained by fitting the multiscale model (Eq. 1)35 to total viral load kinetic data in the SPARE and SYNERGY trials until the end of treatment. Mean population parameter represents the typical value of a parameter in the studied population. The variability of each parameter is shown in the last column. We assumed a log-normal distribution for all parameters except εα and εs, which were assumed to follow logit-normal distribution. RSE: relative standard error in percentage. When a parameter was fixed to values found in literature and was not estimated, the RSE could not be provided and this is indicated by “−”.

From: The paradox of highly effective sofosbuvir-based combination therapy despite slow viral decline: can we still rely on viral kinetics?

 

Mean population parameter (RSE (%))

Covariate testing

Variability (RSE (%))

Tlag

0. 071 (8)

 

0 (−)

log10(V0)

5. 96 (1)

 

0.133 (4)

c

14.4 (12)

 

0.919 (11)

δSOF+LDV±GS-9669

0.141 (9)

p = 0.0025

0.608 (4)

δSOF+RBV or SOF+LDV+GS-9451

0.198 (7)

α

40 (−)

 

0 (−)

ρ

4.44 (9)

 

0.75 (9)

μ

0.87 (9)

 

0 (−)

εα _SOF+RBV

0.9996 (2)

p < 10−10

1.02 (9)

εα _SOF+LDV±DAA

0.98 (5)

εs_ SOF+LDV±DAA

0.997 (3)

 

0.852 (13)

κ

1 (−)

 

0 (−)